Polycomb Group proteins: an evolutionary perspective. Trends Genet ; 23 : — Senthilkumar R , Mishra RK. Novel motifs distinguish multiple homologues of Polycomb in vertebrates: expansion and diversification of the epigenetic toolkit. BMC Genomics ; 10 : A human Polycomb isoform lacking the Pc box does not participate to PRC1 complexes but forms protein assemblies and represses transcription. Epigenetics ; 7 : — Origin of the polycomb repressive complex 2 and gene silencing by an E z homolog in the unicellular alga Chlamydomonas.
Epigenetics ; 5 : — Hennig L , Derkacheva M. Diversity of Polycomb group complexes in plants: same rules, different players? Trends Genet ; 25 : — Butenko Y , Ohad N. Polycomb-group mediated epigenetic mechanisms through plant evolution. Biochim Biophys Acta ; : — Margueron R , Reinberg D. The Polycomb complex PRC2 and its mark in life. The zebrafish genes encoding the Polycomb repressive complex PRC 1.
Recommended for you
Gene ; : 10— Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. Cell Stem Cell ; 10 : 47— Cell Stem Cell ; 10 : 33— Mol Cell ; 45 : — Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell ; 65 : — The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Immunity ; 9 : — Mol Biol Cell ; 18 : — Mel acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells.
Cancer Res ; 67 : — Vincenz C , Kerppola TK. Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Genes Dev ; 25 : — Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.
Blood ; : — Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev ; 20 : — PLoS Genet ; 4 : e EMBO J ; 25 : — A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell ; : 99— Analysis of overrepresented motifs in human core promoters reveals dual regulatory roles of YY1.
Genome Res ; 17 : — A multifaceted protein beyond a transcription factor. Transcription ; 1 : 81— Mol Cell Biol ; 32 : — Hypermethylated in cancer 1 HIC1 recruits polycomb repressive complex 2 PRC2 to a subset of its target genes through interaction with human polycomb-like hPCL proteins. J Biol Chem ; 1 : — REST-mediated recruitment of polycomb repressor complexes in mammalian cells. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. RYBP a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1.
EMBO J ; 18 : — Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi Immunity ; 21 : — Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev ; 8 : — The role of mel, a mammalian Polycomb group gene, during ILdependent proliferation of lymphocyte precursors.
Immunity ; 7 : — Polycomb group gene mel modulates the self-renewal activity and cell cycle status of hematopoietic stem cells. Exp Hematol ; 32 : — Stage-specific expression of polycomb group genes in human bone marrow cells. Blood ; 91 : — Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell ; 6 : — Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice.
J Exp Med ; : — Bmi1 regulates mitochondrial function and the DNA damage response pathway. J Cell Biol ; : 45— BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci ; 30 : — Cell Cycle ; 10 : — Altered cellular proliferation and mesoderm patterning in Polycomb-Mdeficient mice.
Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol ; 22 : — Unique composition of polycomb repressive complex 1 in hematopoietic stem cells. Int J Hematol ; 85 : — CBX7 is a tumor suppressor in mice and humans. J Clin Invest ; : — Role of the chromobox protein CBX7 in lymphomagenesis. Targeted disruption of the mouse homologue of the Drosophila polyhomeotic gene leads to altered anteroposterior patterning and neural crest defects.
Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Exp Hematol ; 29 : 93— Polycomb group gene rae28 is required for sustaining activity of hematopoietic stem cells. Defective long-term repopulating ability in hematopoietic stem cells lacking the Polycomb-group gene rae Eur J Haematol ; 73 : 75— Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion.
Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. De Haan G , Gerrits A. Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann NY Acad Sci ; : — The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease.
Nat Commun ; 3 : The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol ; 21 : — Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol ; 4 : — Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev ; 13 : — Polycomb repressive complex 2 PRC2 restricts hematopoietic stem cell activity.
PLoS Biol ; 6 : e Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. Polycomb proteins in hematologic malignancies. Sauvageau M , Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell ; 7 : — Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Ann Hematol ; 90 : — Leukemia ; 21 : — The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.
Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia ; 25 : — Am J Pathol ; : — Blood ; 97 : — Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J ; 17 : — Lessard J , Sauvageau G.
The emerging role of epigenetics in human autoimmune disorders | Clinical Epigenetics | Full Text
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol ; 81 : — A deeper exploration of the complex epigenetic interactions may be useful for the development of promising treatment strategies targeting the epigenome.
The fundamental work of Farh et al. However, to date, there is still a lot of research necessary in order to provide effective healthcare solutions for such diseases, such as an adequate choice of treatment and a precise prediction of treatment outcomes. Epigenetics will very likely aid to provide further progress in the field of autoimmunity. Until now, only a few studies have been carried out to examine the clinical applicability of epigenetics and its modulators in such autoimmune diseases.
Keeping this concept in mind, more comprehensive and more accessible technologies are recommended to promote advances in the therapeutics leading to prevention by early interventions and reducing both costs and patient morbidity. Taken together, the future of epigenetics in autoimmunity is rapidly increasing. However, it still needs an in-depth investigation to allow novel potential therapeutic opportunities, better than those currently used. Bird A.
Perceptions of epigenetics. Moosavi A, Motevalizadeh AA. Role of epigenetics in biology and human diseases. Iran Biomed J.